Furthermore, NPM1 mutations and FLT3 internal tandem duplication (FLT3-ITD) are less frequently detected in patients with t-AML while regularly identified TP53 mutations are associated with a lower response rate to conventional chemotherapy (Kayser et al. 2011). Here, TP53 is linked to acute myeloid leukemia.